SK Bioscience Appoints Vice President Sangho Ma, Restructures Research Support Organization
SK Bioscience announced on April 6 that it has appointed Sangho Ma, an expert in infectious disease research project management, as Vice President and Head of Research Support at the Bio Research Division.
This appointment was made to strengthen the company's R&D project management (PM) capabilities and open innovation, as well as to establish a comprehensive support system covering the full cycle from research planning and regulatory response to non-clinical and GCLP (Good Clinical Laboratory Practice) operations.
Ma is a seasoned expert who has overseen non-clinical and clinical development projects for pharmaceuticals and vaccines at institutions such as the Korea Health Industry Development Institute, GC Green Cross, and JW Pharmaceutical. He holds a Ph.D. in Pharmacy from Sungkyunkwan University and a master's and bachelor's degree in Chemistry from Hankuk University of Foreign Studies.
SK Bioscience has organized the Research Support Office into the Research Planning Team, Bio Regulatory Management Team, NCS (Non-Clinical Support) Team, and GCLP Team, establishing an integrated and organic research management process. Based on these enhanced research support functions, the company aims to secure a competitive edge in the development of major pipeline products, including a next-generation pneumococcal vaccine, a universal COVID-19 vaccine, RSV preventive antibodies, an Ebola vaccine, and a next-generation influenza vaccine.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, in January, SK Bioscience relocated its headquarters and research center to the Songdo Global R&PD Center, and has since launched full-scale projects related to Ebola, RSV, next-generation influenza, and universal COVID-19 vaccines in collaboration with international organizations and institutions. The 21-valent pneumococcal vaccine 'GBP410', being co-developed with Sanofi, is currently undergoing global Phase 3 clinical trials. The company plans to sequentially apply for IND (Investigational New Drug) approvals and initiate clinical trials for its universal COVID-19 vaccine, next-generation pneumococcal vaccine, and avian influenza vaccine within the year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.